Cargando…

Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections

PURPOSE: To analyze the use of artificial tears in patients undergoing treatment with anti-vascular endothelial growth (anti-VEGF) intravitreal injections. METHODS: Thirty-four eyes undergoing anti-VEGF treatment were analyzed. Each patient underwent a subjective and objective evaluation of the ocul...

Descripción completa

Detalles Bibliográficos
Autores principales: Pastor-Pascual, Francisco, Pastor-Pascual, Rafael, Gálvez-Perez, Patricia, Dolz-Marco, Rosa, Gallego-Pinazo, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719699/
https://www.ncbi.nlm.nih.gov/pubmed/36474999
http://dx.doi.org/10.2147/OPTH.S391082
_version_ 1784843383521411072
author Pastor-Pascual, Francisco
Pastor-Pascual, Rafael
Gálvez-Perez, Patricia
Dolz-Marco, Rosa
Gallego-Pinazo, Roberto
author_facet Pastor-Pascual, Francisco
Pastor-Pascual, Rafael
Gálvez-Perez, Patricia
Dolz-Marco, Rosa
Gallego-Pinazo, Roberto
author_sort Pastor-Pascual, Francisco
collection PubMed
description PURPOSE: To analyze the use of artificial tears in patients undergoing treatment with anti-vascular endothelial growth (anti-VEGF) intravitreal injections. METHODS: Thirty-four eyes undergoing anti-VEGF treatment were analyzed. Each patient underwent a subjective and objective evaluation of the ocular surface, using the Ocular Surface Disease Index (OSDI), Dry Eye Questionnaire (DEQ)-5, tear meniscus height (TMH), first and average non-invasive Keratograph Break-Up Time (NIKBUT), bulbar conjunctival redness, meibography and the Vision Break-Up Time (VBUT). Patients attended 5 visits (days 0, 7, 30, 37, and 60). All patients continued with their intravitreal injection treatment during the study (days 0, 30, and 60). Patients did not receive any artificial tear treatment during the first month of the study, and at the baseline visit they were randomly assigned to one of two study groups to receive either the Systane Hydration or the Viscofresh 10mg/mL formulation. Patients were instructed to instill one drop of the assigned study treatment 3 times a day for 30 days during the second month of the study. RESULTS: According to the Mixed Models for Repeated Measures analysis, there is not enough statistical evidence for any of the parameters examined to determine significant differences between being treated with artificial tears and not being treated (p > 0.05). There is, however, a tendency toward improved outcomes in some parameters when artificial tears were used. OSDI, DEQ-5, TMH, and meibography were not affected by either the type of artificial tear used or by the time (from day 30 to day 60; p > 0.05), but the NIKBUT and VBUT values increased over time during this period regardless of which treatment the patient was receiving. CONCLUSION: The use of artificial tears may help to keep the tear film stable Future studies with larger samples should be conducted to elucidate whether the tendency reported in our study becomes significant.
format Online
Article
Text
id pubmed-9719699
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97196992022-12-05 Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections Pastor-Pascual, Francisco Pastor-Pascual, Rafael Gálvez-Perez, Patricia Dolz-Marco, Rosa Gallego-Pinazo, Roberto Clin Ophthalmol Clinical Trial Report PURPOSE: To analyze the use of artificial tears in patients undergoing treatment with anti-vascular endothelial growth (anti-VEGF) intravitreal injections. METHODS: Thirty-four eyes undergoing anti-VEGF treatment were analyzed. Each patient underwent a subjective and objective evaluation of the ocular surface, using the Ocular Surface Disease Index (OSDI), Dry Eye Questionnaire (DEQ)-5, tear meniscus height (TMH), first and average non-invasive Keratograph Break-Up Time (NIKBUT), bulbar conjunctival redness, meibography and the Vision Break-Up Time (VBUT). Patients attended 5 visits (days 0, 7, 30, 37, and 60). All patients continued with their intravitreal injection treatment during the study (days 0, 30, and 60). Patients did not receive any artificial tear treatment during the first month of the study, and at the baseline visit they were randomly assigned to one of two study groups to receive either the Systane Hydration or the Viscofresh 10mg/mL formulation. Patients were instructed to instill one drop of the assigned study treatment 3 times a day for 30 days during the second month of the study. RESULTS: According to the Mixed Models for Repeated Measures analysis, there is not enough statistical evidence for any of the parameters examined to determine significant differences between being treated with artificial tears and not being treated (p > 0.05). There is, however, a tendency toward improved outcomes in some parameters when artificial tears were used. OSDI, DEQ-5, TMH, and meibography were not affected by either the type of artificial tear used or by the time (from day 30 to day 60; p > 0.05), but the NIKBUT and VBUT values increased over time during this period regardless of which treatment the patient was receiving. CONCLUSION: The use of artificial tears may help to keep the tear film stable Future studies with larger samples should be conducted to elucidate whether the tendency reported in our study becomes significant. Dove 2022-11-30 /pmc/articles/PMC9719699/ /pubmed/36474999 http://dx.doi.org/10.2147/OPTH.S391082 Text en © 2022 Pastor-Pascual et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Pastor-Pascual, Francisco
Pastor-Pascual, Rafael
Gálvez-Perez, Patricia
Dolz-Marco, Rosa
Gallego-Pinazo, Roberto
Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections
title Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections
title_full Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections
title_fullStr Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections
title_full_unstemmed Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections
title_short Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections
title_sort use of artificial tears in patients undergoing treatment with anti-vegf intravitreal injections
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719699/
https://www.ncbi.nlm.nih.gov/pubmed/36474999
http://dx.doi.org/10.2147/OPTH.S391082
work_keys_str_mv AT pastorpascualfrancisco useofartificialtearsinpatientsundergoingtreatmentwithantivegfintravitrealinjections
AT pastorpascualrafael useofartificialtearsinpatientsundergoingtreatmentwithantivegfintravitrealinjections
AT galvezperezpatricia useofartificialtearsinpatientsundergoingtreatmentwithantivegfintravitrealinjections
AT dolzmarcorosa useofartificialtearsinpatientsundergoingtreatmentwithantivegfintravitrealinjections
AT gallegopinazoroberto useofartificialtearsinpatientsundergoingtreatmentwithantivegfintravitrealinjections